RMReinier G. S. Meester

Reinier G. S. Meester

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Reinier G. S. Meester has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RE: The Centers for Medicare and Medicaid Services and others misunderstand stool testing for colorectal cancer

    by Andrew J Piscitello, David K Edwards V, Signe Fransen, Reinier G S Meester

    Andrew J Piscitello, MAT, David K Edwards V, Phd, Signe Fransen, MS, Reinier G S Meester, MS, Phd; RE: the centers for medicare and medicaid services and o


  • Open Access

    Supplementary Tables 1-2 and Supplementary Figures 1-4 from Impact and Recovery from COVID-19–Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis

    by Rosita van Den Puttelaar, Iris Lansdorp-Vogelaar, Anne I. Hahn, Carolyn M. Rutter, Theodore R. Levin, Ann G. Zauber, Reinier G.S. Meester

    Supplementary Table 1. Published estimates of the decrease in CRC screening rates as a result of the COVID-19 pandemic (March-September) identified by our literature search. Supplementary Table 2. Published estimates of the decrease in CRC diagnoses rates as a result of the COVID-19 pandemic (March-September) identified by our literature search. Some studies distinguish between new and all diagnoses. Supplementary Figure 1. Simulated screening in MISCAN: screened with any test (A), fecal immunochemical testing in the past year (FIT) (B), endoscopy in the past 5 years (C), endoscopy in the past 10 years (D), proportion of endoscopies that was colonoscopy (E), and percentage up-to-date with screening (F). Supplementary Figure 2. Simulated incidence (A-C) and mortality rates (D-F) for all three recovery periods were smoothed using a logarithmic regression model. Supplementary Figure 3. Severity of disruption in preventive (panel A) and diagnostic (panel B) services during the disruption period. Supplementary Figure 4. Cumulative excess CRC cases (A) and deaths (B) compared to a scenario without pandemic-induced delays over time for different recovery scenarios.

  • Open Access

    Data from Impact and Recovery from COVID-19–Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis

    by Rosita van Den Puttelaar, Iris Lansdorp-Vogelaar, Anne I. Hahn, Carolyn M. Rutter, Theodore R. Levin, Ann G. Zauber, Reinier G.S. Meester

    Background:Many colorectal cancer–related procedures were suspended during the COVID-19 pandemic. In this study, we predict the impact of resulting delays in screening (colonoscopy, FIT, and sigmoidoscopy) and diagnosis on colorectal cancer–related outcomes, and compare different recovery scenarios.Methods:Using the MISCAN-Colon model, we simulated the US population and evaluated different impact and recovery scenarios. Scenarios were defined by the duration and severity of the disruption (percentage of eligible adults affected), the length of delays, and the duration of the recovery. During recovery (6, 12 or 24 months), capacity was increased to catch up missed procedures. Primary outcomes were excess colorectal cancer cases and –related deaths, and additional colonoscopies required during recovery.Results:With a 24-month recovery, the model predicted that the US population would develop 7,210 (0.18%) excess colorectal cancer cases during 2020–2040, and 6,950 (0.65%) excess colorectal cancer–related deaths, and require 108,500 (8.6%) additional colonoscopies per recovery month, compared with a no-disruption scenario. Shorter recovery periods of 6 and 12 months, respectively, decreased excess colorectal cancer–related deaths to 4,190 (0.39%) and 4,580 (0.43%), at the expense of 260,200–590,100 (20.7%–47.0%) additional colonoscopies per month.Conclusions:The COVID-19 pandemic will likely cause more than 4,000 excess colorectal cancer–related deaths in the US, which could increase to more than 7,000 if recovery periods are longer.Impact:Our results highlight that catching-up colorectal cancer–related services within 12 months provides a good balance between required resources and mitigation of the impact of the disruption on colorectal cancer–related deaths.

  • Open Access

    Comparative benefits, burdens, and harms of emerging blood-based tests for colorectal cancer screening

    by Reinier G S Meester, Andrew J Piscitello, Joseph A Duimstra, Peter S Liang, Aasma Shaukat, Theodore R Levin

    Background: Emerging blood tests may improve colorectal cancer (CRC) screening uptake and outcomes but are less sensitive for advanced precancerous lesions than some currently recommended tests. We examine whether these tests meet expectations for the US Preventive Services Task Force (USPSTF) recommendation. Methods: A decision-analytic model that informed USPSTF was replicated and used to estimate the lifetime benefits (averted CRC cases and deaths, life-years gained [LYG]), burdens (required screening tests and colonoscopies), and harms (colonoscopy-related complications) for annual, biennial, or triennial blood testing through age 45-75 years vs a benchmark of recommended and contemporary stool-based strategies, with colonoscopy screening as the reference. Base-case analyses assumed 100% adherence. Sensitivity analyses evaluated more realistic scenarios. Results: Among benchmark strategies, colonoscopy screening had the most benefit, with an estimated 30 CRC deaths averted, 356 LYG, 4270 colonoscopies required, and 15 complications per 1000 adults; stool-based strategies resulted in 81% to 88% of LYG for colonoscopy, 6829-19 476 screening tests, 1523-1880 colonoscopies, and 9-10 complications. By comparison, annual blood testing resulted in 85% to 87% of LYG for colonoscopy and an intermediate number of screenings, colonoscopies, and complications. Biennial and triennial blood testing provided 57% to 72% of LYG for colonoscopy but resulted in net population benefit under plausible scenarios for increased utilization vs existing strategies. Conclusions: The estimated benefits, burdens, and harms of annual blood testing are within the range of current CRC screening strategies. Biennial and triennial testing should also be considered for recommendation given the potential for increased utilization and net population benefit.


  • Contrasts in colorectal cancer incidence and mortality in screening trials of sigmoidoscopy vs the Nordic-European Initiative on Colorectal Cancer colonoscopy trial

    by Reinier G S Meester, Eric A Miller, Paul F Pinsky, Robert E Schoen, Uri Ladabaum

    Background: Interim 10-year results from the Nordic-European Initiative on Colorectal Cancer (NordICC), a randomized controlled trial (RCT) of screening colonoscopy, demonstrated a statistically significant reduction in colorectal cancer (CRC) incidence but not mortality, contrary to results from 4 flexible sigmoidoscopy RCTs. Methods: We constructed CRC incidence and mortality Kaplan–Meier curves through 10 years to standardize comparisons across RCTs and examined CRC screen detection and stage. Novel analyses of 1 flexible sigmoidoscopy RCT (Prostate, Lung, Colorectal, and Ovarian cancer screening trial [PLCO]) assessed year-by-year mortality in screen-detected CRCs. Results: At 10 years, all RCTs demonstrated statistically significant CRC incidence reductions with screening (ratio = 0.77, 95% confidence interval [CI] = 0.70 to 0.84, to ratio = 0.82, 95% CI = 0.69 to 0.97, vs control arm; P ≤ .011). Two flexible sigmoidoscopy RCTs and NordICC showed no statistically significant CRC mortality reduction (ratio = 0.84, 95% CI = 0.64 to 1.10, to ratio = 0.90, 95% CI = 0.69 to 1.18; P = .10-0.23). In 3 flexible sigmoidoscopy RCTs and NordICC, relative reductions were greater in CRC incidence than CRC mortality, but only NordICC reported higher CRC mortality with screening vs the control arm for the first 7 years. In contrast, PLCO observed fewer CRC deaths with screening by year 2 (ratio = 0.59; P = .03), and screen-detected CRCs were less often advanced (odds ratio = 0.26; P < .001) or fatal (ratio = 0.50; P < .001). Conclusions: After 10 years, NordICC is similar to 2 flexible sigmoidoscopy RCTs in observing statistically significant reductions in CRC incidence but not CRC mortality. However, only NordICC observed greater CRC mortality with screening vs the control arm for 7 years. Granular analyses of CRC cases and deaths in NordICC, paralleling our PLCO analyses, could provide insight into why CRC mortality results differ in NordICC vs flexible sigmoidoscopy RCTs.


  • Open Access

    Benefits of colorectal cancer screening using fecal immunochemical testing with varying positivity thresholds by age and sex

    by Matthias Harlass, Amy B Knudsen, Daan Nieboer, Luuk A van Duuren, Karen M Kuntz, Carolyn M Rutter, Pedro Nascimento de Lima, Nicholson Collier, Jonathan Ozik, Anne I Hahn, et al.

    Background: Fecal immunochemical test (FIT) performance for colorectal cancer screening varies by age and sex, yet most FIT-based screening programs use uniform positivity thresholds. This study assessed the potential benefits of stratifying FIT thresholds based on age and sex. Methods: We conducted a meta-analysis of FIT sensitivity and specificity at various positivity thresholds by age and sex. We then used these estimates in 2 microsimulation models of colorectal cancer and projected lifetime clinical outcomes, incremental costs, and quality-adjusted life-years (QALYs) gained from age- and sex-stratified FIT strategies. FIT thresholds ranged from 10 to 50 µg hemoglobin per gram of feces. Results: For current uniform FIT screening (20 µg hemoglobin/gram of feces), models projected 85.67 to 122.15 QALYs gained at incremental costs of ‒$982 to $504 per 1000 individuals compared with no screening. At equivalent costs to current uniform screening, only 1 model found stratified FIT approaches cost-effective, yielding a marginal increase of 1.04 and 1.10 QALYs gained/1000 female and male individuals, respectively. At a willingness-to-pay threshold of $100 000/QALYs gained, both models found stratified FIT cutoffs to be the best strategy, with cutoffs being equal to or higher for males and lowest at older ages (70-75 years). Uniform strategies showed comparable effectiveness, falling within 1 quality-adjusted life-day per person of efficient strategies at up to $112 more per person. Results were sensitive to FIT test performance characteristics and 1-time setup costs. Conclusion: Stratifying FIT thresholds by age and sex may be cost-effective compared to current screening. The gain in expected health benefits with stratified FIT screening, however, is likely small.


  • Open Access

    Impact of the serrated pathway on the simulated comparative effectiveness of colorectal cancer screening tests

    by Reinier G S Meester, Uri Ladabaum

    Background: Colorectal cancers (CRCs) arise from adenomas, which can produce fecal occult blood and can be detected endoscopically, or sessile serrated lesions (SSLs), which rarely bleed and may be more challenging to detect. Models informing CRC screening policy should reflect both pathways, accounting for uncertainty. Methods: Novel decision-analytic model of the adenoma and serrated pathways for CRC (ANSER) to compare current and emerging screening strategies, accounting for differential test sensitivities for adenomas and SSLs, and uncertainty. Strategies included colonoscopy every 10 years, stool-DNA/FIT (sDNA-FIT) every 1-3 years, or fecal immunochemical testing (FIT) every year from age 45 to 75 years. Outcomes included CRC cases and deaths, cost-effectiveness (cost/quality-adjusted life-year [QALY] gained), and burden–benefit (colonoscopies/life-year gained), with 95% uncertainty intervals (UIs). Results: ANSER predicted 62.5 (95% UI = 58.8-66.3) lifetime CRC cases and 24.1 (95% UI = 22.5-25.7) CRC deaths/1000 45-year-olds without screening, and 78%-87% CRC mortality reductions with screening. The tests’ outcome distributions overlapped for QALYs gained but separated for required colonoscopies and costs. All strategies cost less than $100 000/QALY gained vs no screening. Colonoscopy was the most effective and cost-effective, costing $9300/life-year gained (95% UI = $500-$21 900) vs FIT. sDNA-FIT cost more than $500 000/QALY gained vs FIT. As more CRCs arose from SSLs, colonoscopy remained preferred based on clinical benefit and cost-effectiveness, but cost-effectiveness improved for a next-generation sDNA-FIT. Conclusion: When the serrated pathway is considered, modeling suggests that colonoscopy is cost-effective vs FIT. In contrast, modeling suggests that sDNA-FIT is not cost-effective vs FIT despite its greater sensitivity for SSLs, even if a substantial minority of CRCs arise from SSLs.


  • Projected Colorectal Cancer Incidence and Mortality Based on Observed Adherence to Colonoscopy and Sequential Stool-Based Screening

    by Reinier G.S. Meester, Iris Lansdorp-Vogelaar, Sidney J. Winawer, Timothy R. Church, John I. Allen, Andrew D. Feld, Glenn Mills, Paul A. Jordan, Douglas A. Corley, Chyke A. Doubeni, et al.

    INTRODUCTION: Modeling supporting recommendations for colonoscopy and stool-based colorectal cancer (CRC) screening tests assumes 100% sequential participant adherence. The impact of observed adherence on the long-term effectiveness of screening is unknown. We evaluated the effectiveness of a program of screening colonoscopy every 10 years vs annual high-sensitivity guaiac-based fecal occult blood testing (HSgFOBT) using observed sequential adherence data. METHODS: The MIcrosimulation SCreening ANalysis (MISCAN) model used observed sequential screening adherence, HSgFOBT positivity, and diagnostic colonoscopy adherence in HSgFOBT-positive individuals from the National Colonoscopy Study (single-screening colonoscopy vs ≥4 HSgFOBT sequential rounds). We compared CRC incidence and mortality over 15 years with no screening or 10 yearly screening colonoscopy vs annual HSgFOBT with 100% and differential observed adherence from the trial. RESULTS: Without screening, simulated incidence and mortality over 15 years were 20.9 (95% probability interval 15.8–26.9) and 6.9 (5.0–9.2) per 1,000 participants, respectively. In the case of 100% adherence, only screening colonoscopy was predicted to result in lower incidence; however, both tests lowered simulated mortality to a similar level (2.1 [1.6–2.9] for screening colonoscopy and 2.5 [1.8–3.4] for HSgFOBT). Observed adherence for screening colonoscopy (83.6%) was higher than observed sequential HSgFOBT adherence (73.1% first round; 49.1% by round 4), resulting in lower simulated incidence and mortality for screening colonoscopy (14.4 [10.8–18.5] and 2.9 [2.1–3.9], respectively) than HSgFOBT (20.8 [15.8–28.1] and 3.9 [2.9–5.4], respectively), despite a 91% adherence to diagnostic colonoscopy with FOBT positivity. The relative risk of CRC mortality for screening colonoscopy vs HSgFOBT was 0.75 (95% probability interval 0.68–0.80). Findings were similar in sensitivity analyses with alternative assumptions for repeat colonoscopy, test performance, risk, age, and projection horizon. DISCUSSION: Where sequential adherence to stool-based screening is suboptimal and colonoscopy is accessible and acceptable—as observed in the National Colonoscopy Study—offering screening colonoscopy can increase screening effectiveness.


  • Differential impact of test performance characteristics on burden-to-benefit tradeoffs for blood-based colorectal cancer screening: A microsimulation analysis

    by Andrew Piscitello, Lauren N Carroll, Signe Fransen, Ben Wilson, Tarun Chandra, Reinier Meester, Girish Putcha

    Objectives: To inform the development and evaluation of new blood-based colorectal cancer (CRC) screening tests satisfying minimum United States (US) coverage criteria, we estimated the impact of the different test performance characteristics on long-term testing benefits and burdens. Methods: A novel CRC-Microsimulation of Adenoma Progression and Screening (CRC-MAPS) model was developed, validated, then used to assess different screening tests for CRC. We compared multiple, hypothetical blood-based CRC screening tests satisfying minimum coverage criteria of 74% CRC sensitivity and 90% specificity, to measure how changes in a test's CRC sensitivity, specificity, and adenoma sensitivity (sizes 1–5 mm, 6–9 mm, ≥10 mm) affect total number of colonoscopies (COL), CRC incidence reduction (IR), CRC mortality reduction (MR), and burden-to-benefit ratios (incremental COLs per percentage-point increase in IR or MR). Results: A blood test meeting minimum US coverage criteria for performance characteristics resulted in 1576 lifetime COLs per 1000 individuals, 46.7% IR and 59.2% MR compared to no screening. Tests with increased CRC sensitivity of 99% ( + 25%) vs. increased ≥10 mm adenoma sensitivity of 13.6% ( + 3.6%) both yielded the same MR, 62.7%. Test benefits improved the most with increases in all-size adenoma sensitivity, then size-specific adenoma sensitivities, then specificity and CRC sensitivity, while increases in specificity or ≥10 mm adenoma sensitivity resulted in the most favorable burden-to-benefit tradeoffs (ratios <11.5). Conclusions: Burden-to-benefit ratios for blood-based CRC screening tests differ by performance characteristic, with the most favorable tradeoffs resulting from improvements in specificity and ≥10 mm adenoma sensitivity.


  • Open Access

    Impact and Recovery from COVID-19–Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis

    by Rosita van Den Puttelaar, Iris Lansdorp-Vogelaar, Anne I. Hahn, Carolyn M. Rutter, Theodore R. Levin, Ann G. Zauber, Reinier G.S. Meester

    Background: Many colorectal cancer–related procedures were suspended during the COVID-19 pandemic. In this study, we predict the impact of resulting delays in screening (colonoscopy, FIT, and sigmoidoscopy) and diagnosis on colorectal cancer–related outcomes, and compare different recovery scenarios. Methods: Using the MISCAN-Colon model, we simulated the US population and evaluated different impact and recovery scenarios. Scenarios were defined by the duration and severity of the disruption (percentage of eligible adults affected), the length of delays, and the duration of the recovery. During recovery (6, 12 or 24 months), capacity was increased to catch up missed procedures. Primary outcomes were excess colorectal cancer cases and –related deaths, and additional colonoscopies required during recovery. Results: With a 24-month recovery, the model predicted that the US population would develop 7,210 (0.18%) excess colorectal cancer cases during 2020–2040, and 6,950 (0.65%) excess colorectal cancer–related deaths, and require 108,500 (8.6%) additional colonoscopies per recovery month, compared with a no-disruption scenario. Shorter recovery periods of 6 and 12 months, respectively, decreased excess colorectal cancer–related deaths to 4,190 (0.39%) and 4,580 (0.43%), at the expense of 260,200–590,100 (20.7%–47.0%) additional colonoscopies per month. Conclusions: The COVID-19 pandemic will likely cause more than 4,000 excess colorectal cancer–related deaths in the US, which could increase to more than 7,000 if recovery periods are longer. Impact: Our results highlight that catching-up colorectal cancer–related services within 12 months provides a good balance between required resources and mitigation of the impact of the disruption on colorectal cancer–related deaths.